Outcomes of Allogeneic Stem Cell Transplant in Patients with Relapsed/Refractory Hodgkin Lymphoma

Background: The aim of this study was to evaluate real-world clinical outcomes and transplant-related complications of allogeneic stem cell transplantation (alloSCT) for Hodgkin lymphoma (HL). Methods: This was a single-centre, retrospective analysis of relapsed and refractory (R/R) HL patients who...

Full description

Bibliographic Details
Published in:	Current Oncology
Main Authors:	Shiliang Ge, Kylie Lepic, Ravi Bhindi, Tobias Berg, Dina Khalaf, Brian Leber, Michael Radford, Irwin Walker, Gwynivere Davies, Alejandro Garcia-Horton
Format:	Article
Language:	English
Published:	MDPI AG 2025-02-01
Subjects:	Hodgkin lymphoma allogeneic stem cell transplant relapse refractory PD-1 inhibitor
Online Access:	https://www.mdpi.com/1718-7729/32/2/118

Similar Items

Outcomes associated with allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma in the era of novel agents
by: Muhammad Salman Faisal, et al.
Published: (2023-04-01)

Analysis of relapsed/refractory Hodgkin lymphoma treated with autologous transplantation: A single-center experience
by: Vishal Kulkarni, et al.
Published: (2020-01-01)

Treatment of Relapsed and Refractory Hodgkin’s Lymphoma in Children
by: NS Kulichkina, et al.
Published: (2016-01-01)

Stem-Cell Transplantation in Adult Patients with Relapsed/Refractory Hodgkin Lymphoma
by: Sonja Genadieva Stavrik, et al.
Published: (2021-10-01)

Third line Treatment in Relapsed/Refractory Hodgkin's Lymphoma and Aggressive non-Hodgkin Lymphoma after 2nd line ESHAP or GEMOX
by: Hamdy Zawam, et al.
Published: (2018-06-01)

TREATMENT OF RELAPSE AND REFRACTORY HODGKIN LYMPHOMA
by: E. A. Baryakh
Published: (2017-06-01)

Assessment of Effectiveness and Adverse Effect of New Combination Chemotherapy (irinotecan, cisplatin, and dexamethasone) in Relapse and Refractory Hodgkin Lymphoma
by: Mahdi Tabarraee, et al.
Published: (2023-07-01)

Refractory/Relapsed Classic Hodgkin Lymphoma Mimicking Disseminated Tuberculosis
by: Mohamed Nazem Alibrahim, et al.
Published: (2025-05-01)

COST-EFFECTIVENESS ANALYSIS OF BRENTUXIMAB VEDOTIN IN ADULTS WITH RELAPSED OR REFRACTORY HODGKIN’S LYMPHOMA
by: G. R. Khachatryan, et al.
Published: (2016-04-01)

CURRENT ROLE OF AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION FOR RELAPSED AND REFRACTORY HODGKIN LYMPHOMA
by: Luca Castagna, et al.
Published: (2015-02-01)

Salvage radiotherapy for relapsed/refractory non‐Hodgkin lymphoma following CD19 chimeric antigen receptor T-cell (CART) therapy
by: Nikhil Yegya-Raman, et al.
Published: (2023-03-01)

GDP versus ESHAP Regimen in Relapsed and/or Refractory Hodgkin lymphoma: A Comparison Study
by: Mani Ramzi, et al.
Published: (2015-03-01)

DL-ICE as a bridge to allogeneic transplantation in relapsed/refractory PTCL: survival outcomes and prognostic factors
by: Tong-Yoon Kim, et al.
Published: (2024-12-01)

The use of immunotherapy for the treatment of refractory forms of Hodgkin lymphoma in real clinical practice.
by: I. A. Kamaeva, et al.
Published: (2021-06-01)

Treatment of relapsed or refractory Hodgkin’s lymphoma with lenalidomide combined with PD-1 monoclonal antibody: a case report and literature review
by: Hongjuan Dong, et al.
Published: (2025-07-01)

Comparison of Ifosfamide, Carboplatin and Etoposide versus Etoposide, Steroid, and Cytarabine Cisplatin as Salvage Chemotherapy in Patients with Refractory or Relapsed Hodgkin's lymphoma
by: Valiollah Mehrzad, et al.
Published: (2017-01-01)

MEPED as salvage therapy for relapsed/refractory Hodgkin’s lymphoma incorporating edited non-oncogene addiction: mTOR as a bottleneck
by: Dennis Christoph Harrer, et al.
Published: (2025-03-01)

Brentuximab Vedotin: New Possibilities for Treatment of Relapses and Refractory Hodgkin’s Lymphomas
by: EA Demina
Published: (2015-10-01)

CLINICAL CHARACTERISTICS AND TREATMENT RESULTS OF PEDIATRIC RELAPSED/REFRACTORY NON-HODGKIN’S LYMPHOMAS
by: T. T. Valiev
Published: (2018-07-01)

Outcome of Pregnancy and Labour in a Patient with Hodgkin’s Lymphoma (Clinical Case)
by: A. A. Borscheva, et al.
Published: (2019-09-01)

The Use of Brentuximab Vedotin in Relapsed/Refractory Hodgkin’s Lymphoma in the Kransnodar Region
by: OD Serdyuk, et al.
Published: (2018-01-01)

The Benefit of Brentuximab Vedotin and Checkpoint Inhibitors in Relapsed/Refractory Hodgkin Lymphoma: A Single-Center Retrospective Study
by: Diana-Marina FORTOES, et al.
Published: (2025-06-01)

The role of radiotherapy in patients with refractory Hodgkin's lymphoma after treatment with brentuximab vedotin and/or immune checkpoint inhibitors
by: Ruizhi Zhao, et al.
Published: (2024-03-01)

Cost-effectiveness of brentuximab vedotin compared with conventional chemotherapy for relapsed or refractory classic Hodgkin lymphoma in China
by: Shitong Xie, et al.
Published: (2024-06-01)

TARGETED THERAPY WITH BRENTUXIMAB VEDOTIN IN RELAPSED AND REFRACTORY FORMS OF CLASSICAL HODGKIN LYMPHOMA
by: E. A. Demina
Published: (2017-11-01)

Successful Treatment of Childhood Hodgkin Lymphoma and Secondary Myelofibrosis Resistant to Intensive Therapy, Including Allogeneic Transplantation
by: Deniz Koçak Göl, et al.
Published: (2025-06-01)

Successful Bridging to Allogeneic Transplantation With Valemetostat in Two Refractory/relapsed Peripheral T-cell lymphoma patients
by: Gianmarco Bagnato, et al.
Published: (2024-01-01)

IEV (Ifosfamide, Epirubicin, VP16) Regimen as Salvage Therapy for Early Relapsed/Refractory non-Hodgkin/Hodgkin Lymphoma
by: Behrooz Najafi, et al.
Published: (2011-10-01)

IEV (Ifosfamide, Epirubicin, VP16) Regimen as Salvage Therapy for Early Relapsed/Refractory non-Hodgkin/Hodgkin Lymphoma
by: Mohammadali Mashhadi, et al.
Published: (2011-09-01)

Outcomes in relapsed Hodgkin's lymphoma treated with autologous and allogeneic hematopoietic cell transplantation at the Pontiﬁcia Universidad Católica de Chile
by: Pablo Ramirez, et al.
Published: (2015-06-01)

Remission of relapsed/refractory classical Hodgkin lymphoma induced by brentuximab vedotin and pembrolizumab combination after allogeneic hematopoietic stem cell transplantation: a case report
by: Federica Giannotti, et al.
Published: (2024-03-01)

Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma in Switzerland, 20 years of experience: 2001–2020
by: Helena Simeunovic, et al.
Published: (2023-02-01)

Single or tandem autologous stem cell transplantation for treating Chinese patients with refractory/relapsed classical Hodgkin lymphoma
by: Chen Zhang, et al.
Published: (2023-05-01)

How I treat relapsed and/or refractory multiple myeloma
by: Hans C. Lee, et al.
Published: (2020-09-01)

CD19 chimeric antigen receptor-T cells as bridging therapy to allogeneic hematopoietic cell transplantation improves outcome in patients with refractory/relapsed B-cell acute lymphoblastic leukemia
by: Jie Liu, et al.
Published: (2024-07-01)

Management of Relapsed Hodgkin Lymphoma During the Second Trimester of Pregnancy: Case Report
by: Fatih Yaman, et al.
Published: (2023-03-01)

Relapse of Hodgkin's disease revealed by skin involvement
by: Ouadii Abakarim, et al.
Published: (2022-09-01)

Clinical features and outcomes of newly diagnosed classical Hodgkin lymphoma patients in Saudi Arabia: a multicenter cohort study
by: Mai Alalawi, et al.
Published: (2025-05-01)

Highly immunosuppressive myeloid cells correlate with early relapse after allogeneic stem cell transplantation
by: Anne-Béatrice Notarantonio, et al.
Published: (2024-05-01)

Allogeneic stem cell transplantation in multiple myeloma: is there still a place?
by: Carmine Liberatore, et al.
Published: (2024-06-01)